PATENT CLAIM ANALYSIS

Application Number: 16316345
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-09
Patent Classification: ["424", "133100"]

Abstract:
The disclosure provides methods of treating tauopathies (e.g. Alzheimer's disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia with Parkinsonism linked to chromosome 17, Pick's Disease, Progressive Supranuclear Palsy, Dementia Pugilistica, Down's Syndrome and others) by administering humanized antibodies. The disclosure also provides the anti-tau humanized antibodies that bind the N-terminal region of tau and also bind to pathological tau aggregates, conformational epitopes and peptides mimicking these epitopes (mimotopes).

Claim (Index 7):
The method of  claim 1 , wherein the humanized antibody variable regions comprises\n (i) The variable region of heavy chain selected from the group consisting of SEQ ID Nos: 38, 40, 42, 44, 46, 48, 50 and 52 (ii) The variable region of light chain selected from the group consisting of SEQ ID Nos: 39, 41, 43, 45, 47, 49, 51 and 53

Metadata:
- Claim Count in Document: 16.0
- Percentile: 99.0
- Lexical Diversity: 1.48214
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14421073', '14092539', '14705615', '14154954', '14412309']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7864728966505637
- 35 USC 102 Novelty (BERT): 0.552674637893886
- Combined Prediction Score: 0.763093070774896
- Mean Citation Score: 400.389598
- Max Citation Score: 416.3997
- Similarity Product: 322.2155545515418

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test